NCT06072898View on ClinicalTrials.gov

A Randomized Neuroimaging Trial of Psilocybin in Depression

PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

March 25, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2028

Conditions
Depressive DisorderMajor Depressive Disorder
Interventions
DRUG

Psilocybin

Psilocybin (\[3-\[2-(dimethylamino)ethyl\]-1H-indol-4-yl\] dihydrogen phosphate), 25mg PO.

OTHER

Microcrystalline cellulose

MCC (excipient), 25mg PO.

BEHAVIORAL

Supportive psychotherapy

Supportive psychotherapy in the form of reassurance, integration, and de-escalatory techniques (if needed). Facilitating rapport and a positive environment.

Trial Locations (1)

M4N3M5

RECRUITING

Sunnybrook Health Sciences Centre, Toronto

All Listed Sponsors
lead

Sunnybrook Health Sciences Centre

OTHER